União Europeia - maltês - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - victrelis huwa indikat għall-kura ta ' l-infezzjoni tal-ġenotip-1 kronika epatite-c (chc), flimkien mal-peginterferon alfa u ribavirin, fil-pazjenti adulti b ' mard tal-fwied kompensat li huma mhux ittrattat minn qabel jew li jkunu fallew terapija qabel.

União Europeia - maltês - EMA (European Medicines Agency)

biopartners gmbh - ribavirin - epatite Ċ, kronika - antivirali għal użu sistemiku - ribavirin biopartners hija indikata għat-trattament ta ' infezzjoni kronika (hcv) epatite-c-virus fl-adulti, tfal tliet snin fl-età u l-eqdem u l-adolexxenti u għandhom jintużaw biss bħala parti mill-dożaġġ tal-kombinazzjoni b ' interferon alfa-2b. monoterapija b'ribavirin m'għandhiex tintuża. hemm l-ebda sigurtà jew effikaċja ta ' informazzjoni dwar l-użu ta ' ribavirin ma ' forom oħra ta ' interferon (i. mhux alfa-2b). naïve patientsadult patientsribavirin biopartners huwa indikat, f'kombinazzjoni ma 'interferon alfa-2b, għall-kura ta' pazjenti adulti bil-tipi kollha ta 'epatite Ċ kronika ħlief-ġenotip 1, li ma ġietx ikkurata qabel, mingħajr dikumpensazzjoni tal-fwied, b'livelli għoljin ta' alanine aminotransferase (alt), li huma pożittivi għall-epatite c virali tal-aċidu ribonuklejku (hcv-rna) (ara sezzjoni 4. 4)tat-tfal tliet snin ta 'età u l-anzjani u l-adolescentsribavirin biopartners huwa intenzjonat biex jintuża, f'kors ta 'kombinazzjoni ma' interferon alfa-2b, għall-kura ta 'tfal minn tliet snin jew akbar u adolexxenti, li kollha tipi ta' epatite Ċ kronika ħlief-ġenotip 1, li ma ġietx ikkurata qabel, mingħajr dikumpensazzjoni tal-fwied, u li huma pożittivi għall-hcv-rna. meta tiddeċiedi li ma li tipposponi it-trattament sakemm il-ħajja adulta, huwa importanti li wieħed jikkunsidra li l-terapija kombinata indotta-inibizzjoni tat-tkabbir. l-riversibbiltà ta ' inibizzjoni tat-tkabbir huwa inċert. id-deċiżjoni li l-kura għandha tittieħed fuq bażi ta'każ b'każ (ara sezzjoni 4. qabel il-kura tal-insuffiċjenza tal-patientsadult patientsribavirin biopartners huwa indikat, f'kombinazzjoni ma 'interferon alfa-2b, għall-kura ta' pazjenti adulti b'epatite c kronika li qabel kienu wrew rispons (bin-normalizzazzjoni ta 'l-alt fl-aħħar tal-kura) għall-monoterapija ta' interferon alfa, iżda li wara rkadew (ara sezzjoni 5.

União Europeia - maltês - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - sklerosi multipla - immunosoppressanti - trattament ta 'pazjenti adulti b'forom ta' sklerożi multipla (rms) li jirkadu b'mard attiv iddefinit minn karatteristiċi kliniċi jew ta 'immaġini. it-trattament ta 'pazjenti adulti b'kmieni sklerosi multipla progressiva primarja (ppms) fit-termini tal-mard tal-tul u l-livell tad-diżabilità, u bl-immaġni karatteristiċi ta' l-attività infjammatorja.

União Europeia - maltês - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran sodium - amilojdożi, familjali - drogi oħra tas-sistema nervuża - onpattro huwa indikat għall-kura ta ' transthyretin medjat amilojdożi (hattr amilojdożi) f'pazjenti adulti bil-istadju ta'l-1 jew l-istadju 2 polinewropatija.

União Europeia - maltês - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaċċini - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. l-użu ta shingrix għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

União Europeia - maltês - EMA (European Medicines Agency)

nova laboratories ireland limited - hydroxycarbamide - anemija, sickle cell - aġenti antineoplastiċi - il-prevenzjoni ta vaso-okklusivi komplikazzjonijiet tal-marda taċ-ċelluli sickle fil-pazjenti ta ' aktar minn 2 snin ta'età.

União Europeia - maltês - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaċċini - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

União Europeia - maltês - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplażmi tas-sider - aġenti antineoplastiċi - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

União Europeia - maltês - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - drogi oħra tas-sistema nervuża - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

União Europeia - maltês - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - drogi oħra tas-sistema nervuża - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.